Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Subramaniam

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.12-03 Phase I/Ii Trial of 177Lu-Dota0-Tyr3-Octreotate (Lutathera) and Nivolumab for Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Related publications

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase I Trial of Temsirolimus and Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer

Chemotherapy
MedicineDrug DiscoveryInfectious DiseasesOncologyPharmacology
2016English

P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2015English

P1.01-46 Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-32 a Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy
OncologyPharmacology
2019English

Outcome Analysis of Phase I Trial Patients With Metastatic KRAS and/or TP53 Mutant Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

OA10.06 a First-In-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy